Literature DB >> 33548158

Hypertrophic cardiomyopathy associated E22K mutation in myosin regulatory light chain decreases calcium-activated tension and stiffness and reduces myofilament Ca2+ sensitivity.

Jiajia Zhang1, Li Wang1, Katarzyna Kazmierczak2, Hang Yun1, Danuta Szczesna-Cordary2, Masataka Kawai3.   

Abstract

We investigated the mechanisms associated with E22K mutation in myosin regulatory light chain (RLC), found to cause hypertrophic cardiomyopathy (HCM) in humans and mice. Specifically, we characterized the mechanical profiles of papillary muscle fibers from transgenic mice expressing human ventricular RLC wild-type (Tg-WT) or E22K mutation (Tg-E22K). Because the two mouse models expressed different amounts of transgene, the B6SJL mouse line (NTg) was used as an additional control. Mechanical experiments were carried out on Ca2+ - and ATP-activated fibers and in rigor. Sinusoidal analysis was performed to elucidate the effect of E22K on tension and stiffness during activation/rigor, tension-pCa, and myosin cross-bridge (CB) kinetics. We found significant reductions in active tension (by 54%) and stiffness (active by 40% and rigor by 54%). A decrease in the Ca2+ sensitivity of tension (by ∆pCa ~ 0.1) was observed in Tg-E22K compared with Tg-WT fibers. The apparent (=measured) rate constant of exponential process B (2πb: force generation step) was not affected by E22K, but the apparent rate constant of exponential process C (2πc: CB detachment step) was faster in Tg-E22K compared with Tg-WT fibers. Both 2πb and 2πc were smaller in NTg than in Tg-WT fibers, suggesting a kinetic difference between the human and mouse RLC. Our results of E22K-induced reduction in myofilament stiffness and tension suggest that the main effect of this mutation was to disturb the interaction of RLC with the myosin heavy chain and impose structural abnormalities in the lever arm of myosin CB. When placed in vivo, the E22K mutation is expected to result in reduced contractility and decreased cardiac output whereby leading to HCM. SUB-DISCIPLINE: Bioenergetics. DATABASE: The data that support the findings of this study are available from the corresponding authors upon reasonable request. ANIMAL PROTOCOL: BK20150353 (Soochow University). RESEARCH GOVERNANCE: School of Nursing: Hua-Gang Hu: seuboyh@163.com; Soochow University: Chen Ge chge@suda.edu.cn.
© 2021 Federation of European Biochemical Societies.

Entities:  

Keywords:  Ca2+ sensitivity; papillary muscle; skinned fiber; stiffness; tension

Mesh:

Substances:

Year:  2021        PMID: 33548158      PMCID: PMC8668163          DOI: 10.1111/febs.15753

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  54 in total

1.  Phosphomimetic-mediated in vitro rescue of hypertrophic cardiomyopathy linked to R58Q mutation in myosin regulatory light chain.

Authors:  Sunil Yadav; Katarzyna Kazmierczak; Jingsheng Liang; Yoel H Sitbon; Danuta Szczesna-Cordary
Journal:  FEBS J       Date:  2018-12-01       Impact factor: 5.542

2.  Familial hypertrophic cardiomyopathy mutations in the regulatory light chains of myosin affect their structure, Ca2+ binding, and phosphorylation.

Authors:  D Szczesna; D Ghosh; Q Li; A V Gomes; G Guzman; C Arana; G Zhi; J T Stull; J D Potter
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

3.  The role of tropomyosin domains in cooperative activation of the actin-myosin interaction.

Authors:  Yusuke Oguchi; Junji Ishizuka; Sarah E Hitchcock-DeGregori; Shin'ichi Ishiwata; Masataka Kawai
Journal:  J Mol Biol       Date:  2011-10-20       Impact factor: 5.469

4.  Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.

Authors:  Chen-Ching Yuan; Priya Muthu; Katarzyna Kazmierczak; Jingsheng Liang; Wenrui Huang; Thomas C Irving; Rosemeire M Kanashiro-Takeuchi; Joshua M Hare; Danuta Szczesna-Cordary
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

5.  The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice.

Authors:  Danuta Szczesna-Cordary; Georgianna Guzman; Jiaju Zhao; Olga Hernandez; Jianqin Wei; Zoraida Diaz-Perez
Journal:  J Cell Sci       Date:  2005-08-02       Impact factor: 5.285

6.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

Authors:  B J Maron; J M Gardin; J M Flack; S S Gidding; T T Kurosaki; D E Bild
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

7.  Three-dimensional structure of myosin subfragment-1: a molecular motor.

Authors:  I Rayment; W R Rypniewski; K Schmidt-Bäse; R Smith; D R Tomchick; M M Benning; D A Winkelmann; G Wesenberg; H M Holden
Journal:  Science       Date:  1993-07-02       Impact factor: 47.728

Review 8.  Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics.

Authors:  Ronny Alcalai; Jonathan G Seidman; Christine E Seidman
Journal:  J Cardiovasc Electrophysiol       Date:  2007-10-04

Review 9.  Regulatory light chains of striated muscle myosin. Structure, function and malfunction.

Authors:  Danuta Szczesna
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2003-06

10.  Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition.

Authors:  Julien Robert-Paganin; Daniel Auguin; Anne Houdusse
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

View more
  2 in total

1.  The effect of gender and obesity in modulating cross-bridge function in cardiac muscle fibers.

Authors:  Jing Xi; Yuanchao Ye; Mohamad Mokadem; Jinxiang Yuan; Masataka Kawai
Journal:  J Muscle Res Cell Motil       Date:  2022-08-22       Impact factor: 3.352

Review 2.  Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Marko Ušaj; Luisa Moretto; Alf Månsson
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.